CN107533065A - 在癌症和免疫恢复中监测cd4+1型t辅助细胞应答的方法 - Google Patents

在癌症和免疫恢复中监测cd4+1型t辅助细胞应答的方法 Download PDF

Info

Publication number
CN107533065A
CN107533065A CN201680001416.2A CN201680001416A CN107533065A CN 107533065 A CN107533065 A CN 107533065A CN 201680001416 A CN201680001416 A CN 201680001416A CN 107533065 A CN107533065 A CN 107533065A
Authority
CN
China
Prior art keywords
her2
response
cancer
cells
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680001416.2A
Other languages
English (en)
Chinese (zh)
Inventor
布莱恩·J·赫尔尼奇
加里·K·科斯基
乔休德普·达塔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2015/020613 external-priority patent/WO2015139003A1/fr
Priority claimed from US14/985,303 external-priority patent/US20160252511A1/en
Application filed by Individual filed Critical Individual
Publication of CN107533065A publication Critical patent/CN107533065A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Physiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201680001416.2A 2015-03-13 2016-03-04 在癌症和免疫恢复中监测cd4+1型t辅助细胞应答的方法 Pending CN107533065A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US14/658,095 2015-03-13
PCT/US2015/020613 WO2015139003A1 (fr) 2014-03-14 2015-03-13 Méthodes de suivi de la réponse lymphocytaire impliquant des lymphocytes t auxiliaires cd4+ de type 1 dans le cancer et la reconstitution immunitaire
USPCT/US2015/020613 2015-03-13
US14/658,095 US20150323547A1 (en) 2014-03-14 2015-03-13 Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration
US14/985,303 US20160252511A1 (en) 2014-03-14 2015-12-30 Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration
US14/985,303 2015-12-30
PCT/US2016/020987 WO2016153761A1 (fr) 2015-03-13 2016-03-04 Méthodes de suivi de la réponse lymphocytaire impliquant des lymphocytes t auxiliaires cd4+ de type 1 dans le cancer et la reconstitution immunitaire

Publications (1)

Publication Number Publication Date
CN107533065A true CN107533065A (zh) 2018-01-02

Family

ID=56978584

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680001416.2A Pending CN107533065A (zh) 2015-03-13 2016-03-04 在癌症和免疫恢复中监测cd4+1型t辅助细胞应答的方法

Country Status (4)

Country Link
JP (1) JP2018515742A (fr)
CN (1) CN107533065A (fr)
CA (1) CA2979676A1 (fr)
WO (1) WO2016153761A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117054649A (zh) * 2023-08-04 2023-11-14 广州中医药大学第一附属医院 一种慢性萎缩性胃炎向胃癌转化标志物及其应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018515421A (ja) * 2015-05-22 2018-06-14 ブライアン ジェイ ツェルニキＣＺＥＲＮＩＥＣＫＩ， Ｂｒｉａｎ， Ｊ． 複数用量注射準備済樹状細胞ワクチンの製造

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100087621A1 (en) * 1993-03-17 2010-04-08 University Of Washington Immune reactivity to her-2/neu protein for diagnosis and treatment of malignancies in which the her-2/neu oncogene is associated
WO2015139003A1 (fr) * 2014-03-14 2015-09-17 Czerniecki, Brian, J. Méthodes de suivi de la réponse lymphocytaire impliquant des lymphocytes t auxiliaires cd4+ de type 1 dans le cancer et la reconstitution immunitaire

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2891462B1 (fr) * 2005-09-30 2009-10-16 Commissariat Energie Atomique Epitopes t cd4+ de la survivine et leurs applications
RU2575978C2 (ru) 2010-03-15 2016-02-27 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Система и способ получения и хранения активированных зрелых дендритных клеток
EP2872532A4 (fr) * 2012-07-10 2016-04-13 Oncotherapy Science Inc Peptides épitopes du cdca1 pour cellules th1 et vaccins les contenant

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100087621A1 (en) * 1993-03-17 2010-04-08 University Of Washington Immune reactivity to her-2/neu protein for diagnosis and treatment of malignancies in which the her-2/neu oncogene is associated
WO2015139003A1 (fr) * 2014-03-14 2015-09-17 Czerniecki, Brian, J. Méthodes de suivi de la réponse lymphocytaire impliquant des lymphocytes t auxiliaires cd4+ de type 1 dans le cancer et la reconstitution immunitaire
CN107073038A (zh) * 2014-03-14 2017-08-18 宾夕法尼亚大学理事会 在癌症和免疫恢复中监测cd4+1型t辅助细胞应答的方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GEBHART, MJP ET AL: "Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer", 《NEW ENGLAND JOURNAL OF MEDICINE》 *
KOSKI, GK ET AL: "A Novel Dendritic Cell-Based Immunization Approach for the Induction of Durable Th1-Polarized Anti-HER-2/neu Responses in Women with Early Breast Cancer", 《JOURNALY OF IMMUNOTHERAPY》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117054649A (zh) * 2023-08-04 2023-11-14 广州中医药大学第一附属医院 一种慢性萎缩性胃炎向胃癌转化标志物及其应用

Also Published As

Publication number Publication date
WO2016153761A1 (fr) 2016-09-29
CA2979676A1 (fr) 2016-09-29
JP2018515742A (ja) 2018-06-14

Similar Documents

Publication Publication Date Title
Sugita et al. NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors
Kruit et al. Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE‐3 protein in patients with detectable metastatic melanoma
Buckanovich et al. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy
Rahma et al. The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors
US20150118244A1 (en) Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients
JP2020124193A (ja) 癌のｃｄ４＋ｔヘルパー１型応答の監視方法および免疫回復
JP2022088665A (ja) がんの治療
Fracol et al. Response to HER-2 pulsed DC1 vaccines is predicted by both HER-2 and estrogen receptor expression in DCIS
US20170261508A1 (en) Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration
JPWO2014098012A1 (ja) ヘルパーｔ細胞の活性化方法
WO2017190074A1 (fr) Lymphangiogenèse pour l'immunomodulation thérapeutique
CN108463228A (zh) 鳞状细胞癌的预后和治疗
O'Shea et al. Phase II trial of nelipepimut-S peptide vaccine in women with ductal carcinoma in situ
TW202210084A (zh) Cd30陽性癌症之治療
US20160252511A1 (en) Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration
US20210163573A1 (en) Identification of immunogenic mhc class ii peptides for immune-based therapy
CN107533065A (zh) 在癌症和免疫恢复中监测cd4+1型t辅助细胞应答的方法
EP4003415A1 (fr) Inhibiteurs de chi3l1 et leurs utilisations
AU2016244182B2 (en) Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration
JP2021043204A (ja) 免疫に基づく療法のための、免疫原性ｍｈｃクラスｉｉペプチドの同定
WO2021132544A1 (fr) Biomarqueur de pronostic du cancer
EP3268464A1 (fr) Méthodes de suivi de la réponse lymphocytaire impliquant des lymphocytes t auxiliaires cd4+ de type 1 dans le cancer et la reconstitution immunitaire
CN116710475A (zh) Sqstm1及其在癌症疗法中的用途
Scholl et al. Is primary chemotherapy useful for all patients with primary invasive breast cancer?
JP2017118841A (ja) 免疫療法の効果予測マーカー

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20180102

RJ01 Rejection of invention patent application after publication